Cover Image
市場調查報告書

老年性黃斑部病變 (VEGF) :流行病學·基於患者之市場預測,治療流程,上市藥·開發平台藥物分析

Age-related macular degeneration (VEGF): Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis

出版商 Datamonitor Healthcare 商品編碼 365199
出版日期 內容資訊 英文 190 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
老年性黃斑部病變 (VEGF) :流行病學·基於患者之市場預測,治療流程,上市藥·開發平台藥物分析 Age-related macular degeneration (VEGF): Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis
出版日期: 2016年04月01日 內容資訊: 英文 190 Pages
簡介

本報告提供老年性黃斑部病變治療藥 (血管內皮層生長因子 (VEGF)) 市場相關調查分析,市場預測,治療,流行病學,上市藥,開發平台藥物趨勢等系統性資訊。

預測:濕性老年性黃斑部病變

  • 摘要整理
  • 市場概要·趨勢
  • 市場定義·手法
  • abicipar pegol
  • Avastin (bevacizumab)
  • brolucizumab
  • Eylea (aflibercept)
  • Fovista (pegpleranib)
  • Lucentis (ranibizumab)
  • squalamine
  • 1次調查手法

治療:濕性老年性黃斑部病變

  • 摘要整理
  • 1次調查手法
  • 疾病定義·診斷
  • 患者區分
  • 目前治療選擇
  • 治療趨勢

流行病學:老年性黃斑部病變

  • 摘要整理
  • 疾病的背景
  • 資訊來源·手法
  • 預測
  • 流行病學者的考察
  • 優點·缺點

上市藥:濕性老年性黃斑部病變

  • 摘要整理
  • 產品概要
  • 產品簡介:Avastin
  • 產品簡介:Eylea
  • 產品簡介:Lucentis
  • 產品簡介:Macugen
  • 產品簡介:Visudyne

開發平台:濕性老年性黃斑部病變

  • 摘要整理
  • 臨床實驗平台概要
  • 濕性臨床實驗設計
  • 濕性的治療的未來
  • 產品簡介 (後期) :Fovista
  • 產品簡介 (後期) :abicipar pegol
  • 產品簡介 (後期) :brolucizumab
  • 產品簡介 (後期) :squalamine

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC5528

Eylea overtakes Lucentis in 2015 to become the highest selling anti-VEGF treatment for wet AMD, just four years after its first launch.

This report addresses the following questions:

  • How do treatment practices vary in the US and EU between the three major VEGF inhibitors?
  • Why has Eylea been able to quickly position itself as a standard-of-care and overtake Lucentis?
  • What factors will contribute to the expansion of the wet AMD market value over the next ten years?
  • What impact will future biosimilar VEGF therapies have on the branded market?
  • How should pipeline therapies position themselves for maximum commercial success?

TABLE OF CONTENTS

FORECAST: WET AGE-RELATED MACULAR DEGENERATION

  • 1. Executive Summary
  • 2. Market Overview and Trends
  • 3. Market Definition and Methodology
  • 4. abicipar pegol
  • 5. Avastin (bevacizumab)
  • 6. brolucizumab
  • 7. Eylea (aflibercept)
  • 8. Fovista (pegpleranib)
  • 9. Lucentis (ranibizumab)
  • 10. squalamine
  • 11. Primary Research Methodology

TREATMENT: WET AGE-RELATED MACULAR DEGENERATION

  • 12. Executive Summary
  • 13. Primary Research Methodology
  • 14. Disease Definition and Diagnosis
  • 15. Patient Segmentation
  • 16. Current Treatment Options
  • 17. Treatment Trends

EPIDEMIOLOGY: AGE-RELATED MACULAR DEGENERATION

  • 18. Executive Summary
  • 19. Disease Background
  • 20. Sources and Methodology
  • 21. Forecast
  • 22. Epidemiologist Insight
  • 23. Strengths and Limitations

MARKETED DRUGS: WET AGE-RELATED MACULAR DEGENERATION

  • 24. Executive Summary
  • 25. Product Overview
  • 26. Product profile: Avastin
  • 27. Product profile: Eylea
  • 28. Product profile: Lucentis
  • 29. Product profile: Macugen
  • 30. Product profile: Visudyne

PIPELINE: WET AGE-RELATED MACULAR DEGENERATION

  • 31. Executive Summary
  • 32. Clinical Pipeline Overview
  • 33. Clinical Trial Design in Wet AMD
  • 34. The Future of Treatment in Wet AMD
  • 35. Product profile (late stage): Fovista
  • 36. Product profile (late stage): abicipar pegol
  • 37. Product profile (late stage): brolucizumab
  • 38. Product profile (late stage): squalamine
Back to Top